Table 1.
Summary of input data used in the model
| Subgroup | Value (lower and upper CI) | Reference |
|---|---|---|
|
Baseline risk of hospitalisation | ||
| CHD infants |
9.7% (7.4%, 12.0%)† |
Feltes et al. 2003 [5] |
| CLD infants |
12.8% (8.8%, 16.8%)† |
IMPACT, 1998 [6] |
| Preterm: <29 wGA |
10.00% (0.7%, 19.3%)† |
MedImmune/Abbott, Data on File. |
| Preterm: 29–32 wGA |
7.69% (2.86%, 12.5%)† |
MedImmune/Abbott, Data on File. |
| Preterm: 33–35 wGA |
7.69% (2.86%, 12.5%)† |
MedImmune/Abbott, Data on File. |
|
Relative risk reduction of RSV hospitalisation with palivizumab prophylaxis | ||
| CHD infants |
45.3% (18.1%, 63.4%)† |
Feltes et al. 2003 [5] |
| CLD infants |
38.5% (5.0%, 60.2%)† |
IMPACT, 1998 [6] |
| Preterm: <29 wGA |
80.39% (0.00%, 96.26%)† |
MedImmune/Abbott, Data on File. |
| Preterm: 29–32 wGA |
79.69% (35.38%, 93.62%)† |
MedImmune/Abbott, Data on File. |
| Preterm: 33–35 wGA |
73.16% (54.87%, 93.09%)† |
MedImmune/Abbott, Data on File. |
|
Mortality rates of children hospitalised due to RSV disease | ||
| CHD infants |
3.72% (1.19%, 6.23%)† |
Wang et al. 2008 [14] |
| CLD infants |
4.00% (3.00%, 5.00%)† |
Wang et al. 2008 [14] |
| Preterm infants |
0.43% (0.23%, 0.63%)† |
Wang et al. 2008 [14] |
|
Life expectancy | ||
| CHD infants |
76.0 years (75.0††, 78.9††)‡ |
Office for National Statistics [25] |
| All other subgroups |
79.0 years (77.9††, 82.0††)‡ |
Office for National Statistics [25] |
|
Risk of RSV-related sequelae | ||
| Increase in resource use |
2 years |
Greenough et al. 2001 [24] |
| Decrease in utility |
5 years |
Greenough et al. 2004 [21] |
|
Drug and administration costs | ||
| Palivizumab (50 mg vial) |
£306.64/pack (£6.13/mg) |
MIMS [27] |
| Palivizumab (100 mg vial) |
£563.64/pack (£5.64/mg) |
MIMS [27] |
| Initial administration by hospital nurse |
£41 (£23, £47) |
Costs of Health and Social Care 2009–2010 [29] |
| Subsequent administration by GP practice nurse |
£31 (£26, £36) |
Costs of Health and Social Care 2009–2010 [29] |
|
Rate of hospital admissions for RSV (% of patients) | ||
| CHD children in general ward |
100% |
Assumption |
| CHD children in Intensive Care Unit (ICU) |
38.14% (28.48%, 47.81%)† |
Feltes CSR [16] |
| All other infants; General ward |
100% |
Assumption |
| All other infants; Intensive Care Unit (ICU) |
27.45% (18.79%, 47.81%)† |
FDA - Palivizumab Clinical Review [2] |
|
Length of stay of hospital admissions for RSV patients | ||
| CHD children in general ward |
12.40 (9.30, 18.99§) ‡ |
FDA - Palivizumab Clinical Review [2] |
| CHD children in Intensive Care Unit (ICU) |
15.19 (11.39, 15.50§)‡ |
FDA - Palivizumab Clinical Review [2] |
| All other infants; General ward |
6.64 (4.98, 8.32§)‡ |
FDA - Palivizumab Clinical Review [2] |
| All other infants; Intensive Care Unit (ICU) |
7.04 (5.28, 8.80§)‡ |
FDA - Palivizumab Clinical Review [2] |
|
Cost per day of RSV hospitalisation | ||
| General ward |
£555¶ (£406*, £1,955*) |
NHS National Schedule of Reference Costs [28] |
| Intensive Care Unit (ICU) |
£2,225 ¶ (£311*, £1,954*) |
NHS National Schedule of Reference Costs [28] |
|
Medical cost of sequelae (recurrent wheeze/asthma) | ||
| Annual per patient cost for all other subgroups |
£14, 015 |
Greenough et al., 2004 [21]; Costs of Health and Social Care 2009–2010 [29]; NHS National Schedule of Reference Costs [28] |
| Annual per patient cost for 33–35 wGA |
£810 (£0, £8,972) |
Shefali-Petal et al., 2011 [22] |
|
Health state utility values (Utility (SE); (Lower and upper CI) | ||
| Non RSV-H patients |
0.95 (0.25)†; (0.03, 1.00‡‡) |
Greenough et al., 2004 [21] |
| Patients admitted with RSV-H | 0.88 – Modelled as 7.37% (0.94%) reduction†; (5.53%, 9.21%§) | Greenough et al., 2004 [21] |
Abbreviations: CI Confidence interval, CHD Congenital heart disease, CLD Chronic lung disease, wGA weeks of gestational age, GP General practitioner, SE Standard error, RSV-H Respiratory syncytial virus hospitalisation. †Beta distribution; ‡ Gamma distribution; Log-normal distribution. †† The lower and upper confidence intervals are based on the average life expectancy of males and females respectively. § Estimated assuming a confidence interval of ± 25%. * Interquartile range. ‡‡ Plausible range.